Skip to main content
Chugai Pharmaceutical on Muck Rack

Chugai Pharmaceutical

As seen in: Trading View, EBioMedicine, The Lancet, MarketScreener
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chugai

Contact Chugai, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement function

|
By Adrian Ho, Chugai Pharmaceutical, Chugai Pharmabody Research, Ken Ohmine
| EBioMedicine Verified
Keywords Complement C1s C1q Antibody Pharmacokinetic pH-dependent Evidence before this study Aberrant activation of the complement classical pathway (CP) is associated with several autoimmune diseases. Sutimlimab is an anti-C1s antibody drug approved for treatment of patients with cold agglutinin disease, an autoimmune haemolytic anaemia with CP-driven destruction of red blood cells.
Open in Who Shared Issue with article?

Renalys Pharma To Be Acquired By Chugai Pharmaceutical

|
By Chugai Pharmaceutical
| Trading View
Renalys Pharma To Be Acquired By Chugai Pharmaceutical RefinitivLess than 1 min read 4519 RENALYS PHARMA TO BE ACQUIRED BY CHUGAI PHARMACEUTICAL RENALYS PHARMA: UPON EXECUTION OF SHARE ACQUISITION, CHUGAI WILL PAY RENALYS JPY 15.0 BILLION IN CASH RENALYS PHARMA:CHUGAI WILL PAY UP TO JPY 16.0 BILLION IN CASH CONTINGENT ON SPARSENTAN REGULATORY MILESTONES & NET SALES IN JAPAN, SOUTH KOREA & TAIWAN © Copyright Thomson Reuters 2025.
Open in Who Shared Issue with article?

HALOZYME THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) | MarketScreener

|
By uncertainties. Actual, Hoffmann-La Roche, Janssen Biotech, Chugai Pharmaceutical
| MarketScreener
(HALO) Delayed Nasdaq - 04:00:00 2023-02-21 pm EST 49.66 USD -0.74% 04:30p HALOZYME THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) AQ 04:27p Halozyme Therapeutics' Q4 Non-GAAP EPS, Revenue Gain; Sets 2023 Guidance MT 04:24p Halozyme Therapeutics : Q4 Earnings Snapshot AQ Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds Summary Most relevant All News Analyst Reco.
Open in Who Shared Issue with article?
See all 4 articles